Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313794 · ClinicalTrials.gov registry record · Phase 2
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00313794 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 49 participants.
The verdict
NCT00313794, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression. Patients who are intolerant to treatment(s) are also included. This is a study for good performance status colorectal cancer patients who have exhausted standard therapy options.
Interventions
- DRUG CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313794
The ClinicalTrials.gov registry entry for NCT00313794 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-675,206 is the first listed.
NCT00313794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313794 about?
NCT00313794 is a clinical study titled "Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment". This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression. Patients who are intolerant to treatment(s) are also included. This is a study for good performance status colorectal ...
What is the current status of trial NCT00313794?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2006-05. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00313794?
The interventions under investigation include: CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00313794?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.